Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Precision Biosciences Inc (DTIL)

Precision Biosciences Inc (DTIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 596,173
  • Shares Outstanding, K 52,480
  • Annual Sales, $ 22,240 K
  • Annual Income, $ -92,880 K
  • 60-Month Beta 1.90
  • Price/Sales 25.91
  • Price/Cash Flow N/A
  • Price/Book 10.09
Trade DTIL with:

Options Overview

Details
  • Implied Volatility 121.25%
  • Historical Volatility 91.29%
  • IV Percentile 67%
  • IV Rank 55.47%
  • IV High 154.81% on 11/03/20
  • IV Low 79.44% on 07/22/20
  • Put/Call Vol Ratio 0.05
  • Today's Volume 218
  • Volume Avg (30-Day) 598
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 5,206
  • Open Int (30-Day) 7,160

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.50
  • Number of Estimates 4
  • High Estimate -0.39
  • Low Estimate -0.64
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -38.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.80 +16.02%
on 03/05/21
15.98 -28.85%
on 02/08/21
-3.61 (-24.10%)
since 02/05/21
3-Month
6.97 +63.13%
on 12/09/20
16.60 -31.51%
on 01/21/21
+3.06 (+36.91%)
since 12/04/20
52-Week
4.45 +155.22%
on 09/04/20
16.60 -31.51%
on 01/21/21
+3.09 (+37.32%)
since 03/05/20

Most Recent Stories

More News
Will Precision BioSciences (DTIL) Report Negative Q4 Earnings? What You Should Know

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DTIL : 11.45 (+3.90%)
Precision BioSciences to Present at Upcoming Virtual Investor Conferences

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS genome editing platform, today announced...

DTIL : 11.45 (+3.90%)
Thinking about buying stock in Energous Corp, Casa Systems, Citius Pharmaceuticals, Creative Realities, or Precision BioSciences?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WATT, CASA, CTXR, CREX, and DTIL.

CASA : 7.60 (-0.26%)
CREX : 2.45 (-7.55%)
DTIL : 11.45 (+3.90%)
CTXR : 1.7800 (+0.56%)
WATT : 3.72 (-0.27%)
Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates

Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company, today announced the publication of a paper in Molecular Therapy describing three-year follow-up data showing long-term...

DTIL : 11.45 (+3.90%)
Precision BioSciences to Present at Guggenheim Healthcare Talks 2021 Oncology Day

Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its proprietary ARCUS genome editing platform, today announced it will participate in...

DTIL : 11.45 (+3.90%)
Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma

Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its wholly proprietary ARCUS genome editing platform, today announced it has received...

DTIL : 11.45 (+3.90%)
Thinking about buying stock in Celsion Corp, Jaguar Health, Precision BioSciences, electroCore, or Lipocine?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSN, JAGX, DTIL, ECOR, and LPCN.

DTIL : 11.45 (+3.90%)
ECOR : 2.0450 (+4.34%)
CLSN : 1.6750 (-9.46%)
JAGX : 1.5850 (-1.55%)
LPCN : 1.4050 (+0.36%)
Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod

The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.

GILD : 64.71 (+2.34%)
LLY : 207.28 (+3.36%)
HALO : 40.75 (+0.84%)
DTIL : 11.45 (+3.90%)
Lilly (LLY) Inks Deal With Merus to Discover Cancer Antibodies

Eli Lilly (LLY) signs a deal with Merus to develop novel T-cell re-directing bispecific antibodies. While Merus will lead early-stage development, Loxo Oncology will take care of further development and...

LLY : 207.28 (+3.36%)
MRUS : 22.51 (+4.55%)
PRVL : 23.00 (-0.09%)
DTIL : 11.45 (+3.90%)
Thinking about buying stock in DBV Technologies, Endra Life Sciences, Precision BioSciences, Sorrento Therapeutics, or Aldeyra Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DBVT, NDRA, DTIL, SRNE, and ALDX.

DBVT : 5.19 (+3.39%)
DTIL : 11.45 (+3.90%)
ALDX : 11.02 (-1.34%)
NDRA : 2.21 (+3.76%)
SRNE : 8.73 (-0.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.

See More

Key Turning Points

3rd Resistance Point 12.47
2nd Resistance Point 11.99
1st Resistance Point 11.51
Last Price 11.45
1st Support Level 10.55
2nd Support Level 10.07
3rd Support Level 9.59

See More

52-Week High 16.60
Fibonacci 61.8% 11.96
Last Price 11.45
Fibonacci 50% 10.53
Fibonacci 38.2% 9.09
52-Week Low 4.45

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar